• 1
    Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298: 176371.
  • 2
    Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339: 52032.
  • 3
    Foster TJ. The Staphylococcus aureus“superbug”. J Clin Invest 2004; 114: 16936.
  • 4
    Hart RG, Foster JW, Luther MF, Kanter MC. Stroke in infective endocarditis. Stroke 1990; 21: 695700.
  • 5
    Fitzgerald JR, Foster TJ, Cox D. The interaction of bacterial pathogens with platelets. Nat Rev Microbiol 2006; 4: 44557.
  • 6
    George NP, Konstantopoulos K, Ross JM. Differential kinetics and molecular recognition mechanisms involved in early versus late growth phase Staphylococcus aureus cell binding to platelet layers under physiological shear conditions. J Infect Dis 2007; 196: 63946.
  • 7
    Kerrigan SW, Clarke N, Loughman A, Meade G, Foster TJ, Cox D. Molecular basis for Staphylococcus aureus-mediated platelet aggregate formation under arterial shear in vitro. Arterioscler Thromb Vasc Biol 2008; 28: 33540.
  • 8
    Rooijakkers SH, Van Kessel KP, Van Strijp JA. Staphylococcal innate immune evasion. Trends Microbiol 2005; 13: 596601.
  • 9
    Rooijakkers SH, Ruyken M, Roos A, Daha MR, Presanis JS, Sim RB, Van Wamel WJ, Van Kessel KP, Van Strijp JA. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat Immunol 2005; 6: 9207.
  • 10
    De Haas CJ, Veldkamp KE, Peschel A, Weerkamp F, Van Wamel WJ, Heezius EC, Poppelier MJ, Van Kessel KP, Van Strijp JA. Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent. J Exp Med 2004; 199: 68795.
  • 11
    Bestebroer J, Poppelier MJ, Ulfman LH, Lenting PJ, Denis CV, Van Kessel KP, Van Strijp JA, De Haas CJ. Staphylococcal superantigen-like 5 binds PSGL-1 and inhibits P-selectin-mediated neutrophil rolling. Blood 2007; 109: 293643.
  • 12
    Langley R, Wines B, Willoughby N, Basu I, Proft T, Fraser JD. The staphylococcal superantigen-like protein 7 binds IgA and complement C5 and inhibits IgA-Fc alpha RI binding and serum killing of bacteria. J Immunol 2005; 174: 292633.
  • 13
    George JN, Nurden AT, Phillips DR. Molecular defects in interactions of platelets with the vessel wall. N Engl J Med 1984; 311: 108498.
  • 14
    Harmon JT, Jamieson GA. The glycocalicin portion of platelet glycoprotein Ib expresses both high and moderate affinity receptor sites for thrombin. A soluble radioreceptor assay for the interaction of thrombin with platelets. J Biol Chem 1986; 261: 132249.
  • 15
    Weeterings C, De Groot PG, Adelmeijer J, Lisman T. The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface. Blood 2008; 112: 322733.
  • 16
    Bradford HN, Pixley RA, Colman RW. Human factor XII binding to the glycoprotein Ib-IX-V complex inhibits thrombin-induced platelet aggregation. J Biol Chem 2000; 275: 2275663.
  • 17
    Baglia FA, Shrimpton CN, Emsley J, Kitagawa K, Ruggeri ZM, Lopez JA, Walsh PN. Factor XI interacts with the leucine-rich repeats of glycoprotein Ibalpha on the activated platelet. J Biol Chem 2004; 279: 493239.
  • 18
    Joseph K, Nakazawa Y, Bahou WF, Ghebrehiwet B, Kaplan AP. Platelet glycoprotein Ib: a zinc-dependent binding protein for the heavy chain of high-molecular-weight kininogen. Mol Med 1999; 5: 55563.
  • 19
    White TC, Berny MA, Tucker EI, Urbanus RT, De Groot PG, Fernandez JA, Griffin JH, Gruber A, McCarty OJ. Protein C supports platelet binding and activation under flow: role of glycoprotein Ib and apolipoprotein E receptor 2. J Thromb Haemost 2008; 6: 9951002.
  • 20
    Simon DI, Chen Z, Xu H, Li CQ, Dong J, McIntire LV, Ballantyne CM, Zhang L, Furman MI, Berndt MC, Lopez JA. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med 2000; 192: 193204.
  • 21
    Pennings MT, Derksen RH, Van Lummel M, Adelmeijer J, VanHoorelbeke K, Urbanus RT, Lisman T, De Groot PG. Platelet adhesion to dimeric beta-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibalpha and apolipoprotein E receptor 2′. J Thromb Haemost 2007; 5: 36977.
  • 22
    Romo GM, Dong JF, Schade AJ, Gardiner EE, Kansas GS, Li CQ, McIntire LV, Berndt MC, Lopez JA. The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin. J Exp Med 1999; 190: 80314.
  • 23
    Pendu R, Terraube V, Christophe OD, Gahmberg CG, De Groot PG, Lenting PJ, Denis CV. P-selectin glycoprotein ligand 1 and beta2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor. Blood 2006; 108: 374652.
  • 24
    Baker HM, Basu I, Chung MC, Caradoc-Davies T, Fraser JD, Baker EN. Crystal structures of the staphylococcal toxin SSL5 in complex with sialyl Lewis X reveal a conserved binding site that shares common features with viral and bacterial sialic acid binding proteins. J Mol Biol 2007; 374: 1298308.
  • 25
    Munday AD, Berndt MC, Mitchell CA. Phosphoinositide 3-kinase forms a complex with platelet membrane glycoprotein Ib-IX-V complex and 14-3-3zeta. Blood 2000; 96: 57784.
  • 26
    Urbanus RT, Pennings MT, Derksen RH, De Groot PG. Platelet activation by dimeric beta2-glycoprotein I requires signaling via both glycoprotein Ibalpha and apolipoprotein E receptor 2′. J Thromb Haemost 2008; 6: 140512.
  • 27
    Weeterings C, Adelmeijer J, Myles T, De Groot PG, Lisman T. Glycoprotein Ibalpha-mediated platelet adhesion and aggregation to immobilized thrombin under conditions of flow. Arterioscler Thromb Vasc Biol 2006; 26: 6705.